for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MeiraGTx Holdings PLC

MGTX.O

Latest Trade

15.44USD

Change

0.00(0.00%)

Volume

199,279

Today's Range

15.23

 - 

16.32

52 Week Range

11.60

 - 

24.89

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
15.44
Open
15.55
Volume
199,279
3M AVG Volume
4.56
Today's High
16.32
Today's Low
15.23
52 Week High
24.89
52 Week Low
11.60
Shares Out (MIL)
44.45
Market Cap (MIL)
700.51
Forward P/E
-7.65
Dividend (Yield %)
--

Next Event

Q4 2021 MeiraGTx Holdings PLC Earnings Release

Latest Developments

More

MeiraGTx Announces Positive Preliminary Data from the Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

MeiraGTx Reports Q3 Basic And Diluted Net Loss Per Ordinary Share Of $0.59

Meiragtx Holdings - Q2 Loss Per Share $0.46

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MeiraGTx Holdings PLC

MeiraGTx Holdings plc is a clinical-stage gene therapy company. The Company develops gene therapy treatments for a range of inherited and acquired disorders. It is focused on developing therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia, radiation treatment for head and neck cancers and neurodegenerative diseases, such as amyothrophic lateral sclerosis (ALS). It is also developing transformative technology to enable the use of small molecules to turn gene therapy product candidates on and off. It is focused on three areas of unmet medical needs, including inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases. Its product candidates include AAV-CNGB3, AAV-CNGA3, AAV-RPGR, AAV-RPE65, AAV-AQP1 and AAV-UPF1.

Industry

Biotechnology & Drugs

Contact Info

450 E 29th St Fl 15

NEW YORK, NY

10016-8367

United States

http://meiragtx.com/

Executive Leadership

Keith R. Harris

Independent Chairman of the Board

Alexandria Forbes

President, Chief Executive Officer, Director

Richard Giroux

Chief Financial Officer, Chief Operating Officer

Robert J. Wollin

General Counsel, Secretary

Stuart Naylor

Chief Development Officer

Key Stats

1.86 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-4.470

2019

-1.650

2020

-1.540

2021(E)

-2.060
Price To Earnings (TTM)
--
Price To Sales (TTM)
34.26
Price To Book (MRQ)
3.72
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-32.69
Return on Equity (TTM)
-26.87

Latest News

Latest News

BRIEF-Meiragtx Holdings Reports Q1 Loss Per Share Of $0.43

* Q1 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA

BRIEF-MeiraGTx Says It Believes Capital Sufficient To Fund Operating Expenses, Capital Expenditure Requirements Into 2022

* MEIRAGTX HOLDINGS PLC - COMPANY BELIEVES ITS CAPITAL WILL BE SUFFICIENT TO FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO 2022 Source text for Eikon: Further company coverage:

BRIEF-Meiragtx Announces Priority Medicines, Advanced Therapy Medicinal Product Designations Granted By European Medicines Agency To Aav-Rpgr Gene Therapy

* MEIRAGTX ANNOUNCES PRIORITY MEDICINES (PRIME) AND ADVANCED THERAPY MEDICINAL PRODUCT (ATMP) DESIGNATIONS GRANTED BY THE EUROPEAN MEDICINES AGENCY TO AAV-RPGR GENE THERAPY FOR THE TREATMENT OF X-LINKED RETINITIS PIGMENTOSA

Pfizer, Novartis lead $2 billion spending spree on gene therapy production

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.

FOCUS-Pfizer, Novartis lead pharma spending spree on gene therapy production

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up